Craig-Hallum Maintains Biodesix(BDSX.US) With Buy Rating, Announces Target Price $3
Biodesix Analyst Ratings
Scotiabank Maintains Biodesix(BDSX.US) With Buy Rating, Cuts Target Price to $3
Scotiabank Initiates Biodesix at Sector Outperform With $3 Price Target
Lake Street Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $3
Lake Street Sticks to Its Buy Rating for Biodesix (BDSX)
Craig-Hallum Maintains Biodesix(BDSX.US) With Buy Rating
Craig-Hallum Maintains Biodesix(BDSX.US) With Buy Rating
Biodesix Analyst Ratings
Craig-Hallum Initiates Biodesix(BDSX.US) With Buy Rating, Announces Target Price $3
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Biodesix (BDSX) and CVRx (CVRX)
Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.
Biodesix Analyst Ratings
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target
Buy Rating Justified by Biodesix's Market Leadership and Strong Growth Prospects
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Petiq (PETQ) and Biodesix (BDSX)
Buy Rating Affirmed for Biodesix on Robust Q1 Performance and Market Position Strength
Biodesix (BDSX.US) was first covered by Lake Street and was given a buy rating, with a target price of $3.00.
Biodesix Analyst Ratings
Lake Street Initiates Coverage On Biodesix With Buy Rating, Announces Price Target of $3